Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp amilial combined hyperlipidemia (FCH) is the most common polygenic inherited disorder of lipid metabolism, with an estimated prevalence of 0.5-2.0% in the general population. 1 FCH is characterized by hypercholesterolemia and/or hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), high apolipoprotein B (apoB) and atherogenic small dense low-density lipoprotein (LDL) particles. 1,2 Additionally, FCH is associated with a cluster of metabolic abnormalities, such as obesity, insulin resistance, diabetes, hypertension and metabolic syndrome (MetS). 1-5
164
SKOUMAS I et al.
(≥3 years) were screened for enrollment in the study. All subjects were Caucasian and were not taking any hypolipidemic medication at first visit (never-treated patients or untreated patients for ≥3 months). Patients with known cardiovascular disease were also included. In all participants, a complete medical history had been obtained and a detailed physical examination had been performed during their first visit. During the follow-up, all patients were treated with dietary modifications and hypolipidemic treatment as clinically indicated.
Hard cardiovascular endpoints, such as acute MI (AMI) and cardiovascular death were recorded. All events were confirmed by the patient's medical records or death certificates. The outcome of this study was the combined endpoint of AMI and/or cardiovascular death. The study was approved by the Ethics committee of Hippokration Hospital.
Diagnosis of FCH
FCH was diagnosed according to the following criteria: 1,12-14 (1) total cholesterol and/or triglyceride >90 th percentile according to gender and age in more than 2 measurements, according to the upper levels used in the Prospective Cardiovascular Munster (PROCAM) study; 15 and (2) presence of type IIa, IIb, or IV hyperlipidemia in at least 1 first-degree relative; and/or (3) familial history of early atherosclerotic disease before the age of 60 years.
Diagnostic Criteria of Risk Factors and CAD
The diagnosis of hypertension and diabetes was based on current guidelines. 16, 17 Systolic and diastolic blood pressures (SBP and DBP) were measured with a mercury sphygmomanometer in the sitting position after a 10-min rest and the mean of 3 consecutive measurements 1 min apart was calculated. Subjects who had arterial blood pressure >140/90 mmHg on >2 consecutive consultations or abnormal 24-h ambulatory measurements or who were on anti-hypertensive medication were considered hypertensive. Patients with fasting blood glucose ≥126 mg/dl (7.0 mmol/L) on >2 consecutive visits or 2-h plasma glucose >200 mg/dl (11.1 mmol/L) during an oral glucose tolerance test, or who were on anti-diabetic medication, were considered diabetic.
MetS was defined according to the American Heart Association and the National Heart, Lung, and Blood Institute modified criteria. 18 Diagnosis was established when at least 3 of the following risk factors were present: (1) waist circumference ≥102 cm (40 in.) in men and ≥88 cm (35 in.) in women; (2) elevated triglyceride level ≥150 mg/dl (1.7 mmol/L) or on medication for elevated triglycerides; (3) HDL-C <40 mg/dl in men and <50 mg/dl in women; (4) elevated blood pressure ≥130 mmHg for SBP or ≥85 mmHg for DBP or on anti-hypertensive treatment in a patient with a history of hypertension; and (5) elevated fasting glucose ≥100 mg/dl or on anti-diabetic treatment.
All subjects without an unequivocal history of CAD underwent a treadmill electrocardiogram stress test. Patients with a positive test were then referred for an imaging stress test (myocardial perfusion scintigraphy or dobutamine stress echocardiography) and then for coronary angiography if required. CAD was defined as (1) documented history of coronary revascularization; or (2) history of previous MI plus q waves at electrocardiogram or hypokinesia/akinesia in cardiac ultrasound; or (3) abnormal coronary angiogram (stenosis of >50% in an epicardial coronary artery); or (4) symptoms suggestive of angina plus 2 positive stress tests.
Biochemistry
During the first visit, blood samples were collected from the antecubital vein between 8 a.m. and 10 a.m. in a sitting position after 12 h of fasting and abstinence from alcohol. Serum total cholesterol, HDL-C and triglycerides were measured using a chromatographic enzymic method in a Technicon automatic analyzer RA-1000 (Dade Behring, Marburg, Germany). When triglyceride level was <400 mg/dl, LDL-cholesterol (LDL-C; mg/dl) was calculated using the Friedewald formula: (total cholesterol in mg/dl) -(HDL-C in mg/dl) -(triglycerides in mg/dl)/5. For patients with a triglycerides level >400 mg/dl, no LDL-C value was introduced in analysis. ApoA1 and ApoB and lipoprotein (a) were measured using a latex enhanced turbidimetric immunoassay (BNII; Dade Behring, Germany). All biochemical measurements were carried out in the same laboratory that followed the criteria of the World Health Organization Lipid Reference Laboratories.
Statistical Analysis
Normally distributed continuous variables are presented as mean ± SD, and categorical variables as relative frequencies (percentages). Continuous variables were tested for normality of distribution using the Kolmogorov-Smirnov criterion. Skewed variables are expressed as median (25 th -75 th percentile) and were log-transformed before any analysis. Differences in continuous variables between 2 groups were assessed using 2-tailed Student's unpaired t-test. The relationship between categorical variables was evaluated on 2-tailed Pearson's chi-square test or Fischer's exact test. Survival curves were estimated using the Kaplan-Meier method, and were compared using the log-rank test. Predictors of the combined endpoint were identified and the respective adjusted hazard ratios (HRs) were calculated using the multivariate Cox proportional hazards model. P<0.05 was considered statistically significant. Statistical analysis was performed using SPSS 17.0 for Windows (SPSS, Chicago, IL, USA).
Results
A total of 695 FCH patients (455 male; 240 female) older than 17 years with adequate follow-up (≥3 years) were enrolled in the study (Figure 1 ). They had a mean age of 48.9±10.9 years (range, 17-79 years) at their first visit. The mean duration of follow-up was 9.0±3.7 years (range, 3-20 years). In total, 21 deaths (3.0% of the total group; 18 cardiovascular deaths and 3 deaths from cancer), and 37 AMIs (5.3% of the total group) were recorded in those 695 patients during the follow-up, whereas 41 patients (5.9% of the total) reached the combined endpoint (AMI and/or cardiovascular death). Clinical subject characteristics according to the presence of the combined endpoint during the follow-up are listed in Table 1 .
FCH patients who reached the combined endpoint differed from FCH patients who did not in terms of age, gender, waist and waist-to-hip ratio and fasting glucose ( Table 1) . Furthermore FCH patients with events had a higher prevalence of hypertension, diabetes and MetS compared with FCH patients without events. The 2 groups did not differ in the prevalence of smoking. Most combined endpoints occurred in FCH patients with established CAD at first visit ( Table 1) . Thirty-one of the 118 FCH patients with known CAD reached the combined endpoint, compared with only 10 of the 570 FCH patients without CAD (26.3% vs. 1.8%, P<0.001).
Interestingly, there was no significant difference in the level of total cholesterol, triglycerides, non-HDL-C, apoB and lipoprotein (a) between patients with and without events. In contrast, FCH patients who reached the combined endpoint had lower HDL-C compared with those who did not ( Table 1) . On multivariate Cox proportional analysis, higher HDL-C was associated with a lower risk of combined endpoint independent of age, gender and presence of CAD at enrollment (adjusted HR, 0.956 95% confidence interval [CI]: 0.918-0.997, P=0.036).
We analyzed each cardiometabolic risk factor separately in order to evaluate its impact on FCH. 
SKOUMAS I et al.

Hypertension
Survival analysis (Kaplan-Meier) showed that the incidence of the combined endpoint (AMI and/or death) was higher in FCH patients with hypertension compared to patients without hypertension (12.2% vs. 2.9%, log-rank P<0.001; Figure 2 ). Multivariate analysis (Cox regression) showed that the presence of hypertension was a predictor of outcome in FCH patients independent of age, gender and HDL-C (adjusted HR, 3.03; 95% CI: 1.48-6.23, P=0.002). The association between hypertension and the combined endpoint remained significant even after inclusion of presence of CAD at enrolment in the model (adjusted HR, 3.00; 95% CI: 1.46-6.17, P=0.003; Table 2 ).
Diabetes
The incidence of the combined endpoint was higher in FCH patients with diabetes compared to non-diabetic patients (14.5% vs. 5.0%, log-rank P=0.002; Figure 2 ). Cox regression analysis showed that the presence of diabetes at enrollment predicted AMI and/or cardiovascular death at follow-up independent of age, gender and HDL-C (adjusted HR, 2.53; 95% CI: 1.24-5.14, P=0.01). The association between diabetes and the combined endpoint, however, did not remain significant after inclusion of the presence of CAD at enrollment in the model (adjusted HR, 1.61; 95% CI: 0.77-3.41, P=0.21; Table 2 ).
MetS
The incidence of the combined endpoint was higher in FCH patients with MetS compared to patients without MetS (9.1% vs. 2.8%, log-rank P=0.005; Figure 2 ). Univariate data in Figure 2 show that hypertension and diabetes had a greater contribution to the occurrence of combined endpoint than MetS. This is because, due to the pathophysiology of FCH, most FCH patients meet the American Heart Association and the National Heart, Lung, and Blood Institute modified criteria for triglyceride and HDL-C level, and thus, multiple risk factors cluster P-values by log-rank test. Table 2 ).
Specific Subgroups
Sixty-nine patients belonged to families with 2 or more relatives enrolled in this study. Four of those patients reached the combined endpoint. Analysis after excluding those 69 patients confirmed the independent association between hypertension, MetS and the combined endpoint (data not shown), indicating that inclusion of those subjects in the study did not bias the present results.
The combined endpoint occurred in 33 men and in 8 women (7.3% of men vs. 3.3% of women, P=0.037). Gender-specific analysis showed that in men, hypertension was associated with the combined outcome independently of age, HDL-C and presence of CAD (adjusted HR 2.78, 95% CI: 1.29-6.00, P=0.009). In contrast, MetS was not an independent predictor of the combined endpoint in men (adjusted HR, 1.49; 95% CI: 0.61-3.66, P=NS). In contrast, in women, hypertension had an association with the combined endpoint, but this association had a borderline statistical significance with broad 95%CI (adjusted HR, 6.19; 95% CI: 0.72-53.32, P=0.09), because of the small number of events in women (only 8 events). Although MetS had a significant univariate association with combined endpoint in women (P=0.014; Fischer's exact test), no multivariate analysis could be conducted because all 8 events occurred in women who had MetS. Gender-specific analyses, however, are underpowered, especially in women, and the aforementioned findings cannot be conclusive.
Discussion
In this study of a large Greek FCH patient group, we demonstrated that the incidence of major cardiovascular events was higher in FCH patients with cardiometabolic risk factors such as hypertension, diabetes or MetS, compared to patients without those risk factors. Hypertension and MetS were significant predictors of major cardiovascular events independently of age, gender, and presence of previous CAD. Interestingly, there was no significant difference in the level of lipids at enrollment (except in HDL-C) between patients with and without events.
FCH is a polygenic disorder of lipid metabolism, which was first reported in 1973 to describe a mixed pattern of lipid abnormalities in 47 Seattle families with a history of MI. 19 Since then, several studies have reported a high risk of CAD in FCH patients. 4,8,9,11 Age, gender, diabetes, 6,10 and lipid variables such as triglycerides, 7 total cholesterol and lipoprotein (a) 11 have been shown to correlate with prevalent CAD in cross-sectional studies. Longitudinal studies assessing the ability of risk factors/lipid levels for prediction of hard cardiovascular endpoints, however, are scarce. The Austin et al study is an important longitudinal study with a 20-year follow-up, which found a significant adjusted relative cardiovascular mortality risk of 1.7 in siblings and offspring of FCH patients compared with spouse control subjects. 9 That study found a lack of association between triglyceride level and cardiovascular mortality, but did not identify any independent predictors of cardiovascular events in FCH patients. 9 To our knowledge, the present study is the first longitudinal study to evaluate and identify independent predictors of hard cardiovascular events in FCH patients. Beyond the lipid abnormalities, FCH phenotype is accompanied by obesity, insulin resistance, diabetes, hypertension and MetS, 1-5 which are established predictors of cardiovascular risk. Accordingly, the question as to whether the altered lipid levels or the accompanying metabolic risk factors contribute more to the increased incidence of cardiovascular outcomes is clinically relevant, because the answer to that question may guide therapeutic interventions. Although the presence of established cardiovascular disease was -expectedly -the single most important predictor of cardiovascular risk in the present patients, the present data demonstrate that hypertension and MetS were significant predictors of cardiovascular outcomes in addition to low HDL-C, independent of previous CAD and other covariates. Increased visceral adipose tissue and insulin sensitivity, as well as mediators such as upstream stimulatory factor protein 1, may contribute to the pathophysiological background of the link between those cardiometabolic risk factors and cardiovascular risk. 5,20-23 Furthermore, the level of fatty acidbinding protein 4, an adipocyte-derived protein related to glucose and lipid metabolism, is increased in patients with FCH or MetS, 24,25 and may explain in part the relationship between MetS and major cardiovascular events in the present FCH patients. Although the present study did not prove a causal relationship between hypertension, MetS and cardiovascular risk, it clearly underscores their predictive role for the progression of atherosclerosis and the clinical manifestation of AMI/ cardiovascular death.
We found a 3.0% incidence of cardiovascular death and a 5.9% incidence of major cardiovascular events (cardiovascular death and non-fatal MI) during a 9-year follow up. Austin et al reported a 14.9% incidence of cardiovascular mortality during a 20-year follow up, 9 which may be explained by the longer follow-up and by the lack of effective lipid-lowering medications in the 1970 s.
The strengths of the present study include the large group studied, the long follow-up, and the extensive diagnostic workup for evaluation of occult CAD in patients without established CAD at enrollment. We should, however, acknowledge some limitations. This study was performed in a tertiary center and referral biases cannot be excluded. Accordingly, the estimated prevalence of CAD may not reflect accurately the prevalence in the general FCH population. Although we noticed some differences between men and women (strong association of the combined endpoint with hypertension in men and with MetS in women), the gender-specific analysis is perhaps underpowered, especially for women, and those findings are not conclusive. In general, the total number of events was not sufficient to reach indisputable conclusions, and there is a definite need for larger studies.
Conclusion
The present study indicates that cardiometabolic risk factors such as hypertension and MetS are independent predictors of adverse hard cardiovascular endpoints in FCH patients. Among SKOUMAS I et al.
lipid variables, total cholesterol, triglyceride and non-HDL-C in untreated patients are not related to outcomes, but low HDL-C is an independent predictor of risk. These findings provide potentially useful clinical information in terms of risk assessment and therapy guidance in FCH patients.
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